|
|
|
Bayer, CRGN Team on Toxicity Test
|
Business New Haven
9/30/2002
By: BNH
|
NEW HAVEN ‹ Bayer AG and CuraGen Corp. have announced that CuraGen scientists, in collaboration with Bayer s toxicologists, have developed a technology capable of predicting a drug compound s potential for toxicity. The Predictive Toxicogenomics Screen evaluates drug compound toxicities using very small quantities of compounds that are available immediately after high-throughput drug screening and well in advance of the expensive drug scale-up required for mammalian safety experiments.
Using the Predictive Toxicogenomics Screen early in the drug-development process, scientists can rank-order compounds by their predicted safety profiles. By providing scientists with additional insight into a drug s toxicity, this technology has the potential to save millions of dollars in R&D expenses.
Bayer and CuraGen scientists have completed evaluating more than 150 preclinical drug compounds with the Predictive Toxicogenomics Screen and have ranked these compounds according to their potential for toxicity. Based upon the success achieved through the initial application of this predictive technology, Bayer and CuraGen scientists are now applying the technology to conduct drug-toxicity evaluations on Bayer s small-molecule research pipeline. CuraGen received a milestone payment of $2.9 million from Bayer for successfully developing this technology and industrializing it into a high-throughput format.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
